Blood pressure

Life Time Fall 60day Challenge National Winners Among Thousands Entering 2022 Holiday Season Healthier and Happier

Retrieved on: 
Friday, December 2, 2022

CHANHASSEN, Minn., Dec. 2, 2022 /PRNewswire/ -- Nearly 20,000 people across the U.S. and Canada are entering the holiday season feeling happier and healthier after participating in Life Time's (NYSE: LTH) 60day Challenge. Five people have been named national winners in the challenge by a panel of Life Time coaches - taking home prizes valued at nearly $6,000.

Key Points: 
  • Five people have been named national winners in the challenge by a panel of Life Time coaches - taking home prizes valued at nearly $6,000.
  • The Life Time 60day provides daily support, resources, and motivation for anyone looking to jumpstart their wellness goals and live a healthier life.
  • He ended up losing weight, finding a support community at Life Time and has plans to enter his first pickleball tournament.
  • Amanda Monroe (Fort Worth, TX) Before the 60day Challenge, Monroe had a back injury and suffered a lot of pain.

Active Health Monitoring System Market to Grow at a Surprising Growth of USD 80217.67 Million by 2030, Growth Factors, Segmentation, Size, Share, Trends and Opportunity Analysis

Retrieved on: 
Friday, December 2, 2022

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.

Key Points: 
  • Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
  • We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
  • Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
  • Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Active Health Monitoring System Market to Grow at a Surprising Growth of USD 80217.67 Million by 2030, Growth Factors, Segmentation, Size, Share, Trends and Opportunity Analysis

Retrieved on: 
Friday, December 2, 2022

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.

Key Points: 
  • Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches.
  • We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
  • Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
  • Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.

Base Healthcare Begins Its Mission to Raise Awareness of Testosterone Deficiency and Improve Patient Outcomes

Retrieved on: 
Friday, December 2, 2022

Base Healthcare states that it is working to address low testosterone, or hypogonadism , in the United States because the condition currently affects approximately 39% of men 45 years and older.

Key Points: 
  • Base Healthcare states that it is working to address low testosterone, or hypogonadism , in the United States because the condition currently affects approximately 39% of men 45 years and older.
  • Base Healthcare's programs incorporate education on testosterone levels in America, including their decline since the 1970s due to the public's increasing stress levels and rates of obesity.
  • The services offered by Base Healthcare center around its patient engagement platform, whose dashboard allows members to monitor their improvement in the company's four pillars: sleep, stress, nutrition, and exercise.
  • Base Healthcare is a men's virtual health platform that focuses on foundational health and optimization using an FDA-approved oral testosterone therapy and patient-centered health coaching.

RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Retrieved on: 
Thursday, December 1, 2022

Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.

Key Points: 
  • Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Advise UPNEEQ patients with cardiovascular disease, orthostatic hypotension, and/or uncontrolled hypertension or hypotension to seek medical care if their condition worsens.
  • Advise patients to seek medical care if signs and symptoms of potentiation of vascular insufficiency develop.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

Good Measures Launches the Good Food Prescription Program, a High-Impact, Scalable, and Comprehensive Food as Medicine Solution

Retrieved on: 
Thursday, December 1, 2022

Good Measures , a digital health company, announced the launch of its Good Food Prescription program for health plans and employers.

Key Points: 
  • Good Measures , a digital health company, announced the launch of its Good Food Prescription program for health plans and employers.
  • By choosing our Good Food Prescription program, health plans such as WellCare of Kentucky are showing their commitment to food as medicine as a way to prevent disease, slow disease progression, and improve health equity.
  • Good Measures first launched the Good Food Prescription program with WellCare of Kentucky to improve blood pressure within its Medicaid population and to support a broader health equity strategy.
  • Were thrilled to help power Good Measures Good Food Prescription program with Care Carts, said Sarah Mastrorocco, VP of Health at Instacart.

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference

Retrieved on: 
Thursday, December 1, 2022

About Rhythm PharmaceuticalsRhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. Rhythm’s precision medicine, setmelanotide, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). The European Commission (EC) and Great Britain’s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity and is leveraging the Rhythm Engine and the largest known obesity DNA database -- now with approximately 45,000 sequencing samples -- to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. Rhythm’s headquarters is in Boston, MA.

Key Points: 
  • A replay of the webcast will be available on the Rhythm website for 30 days following the presentation.
  • 2022 Rhythm Pharmaceuticals, Inc. All Rights Reserved.
  • Inthe United StatesandEurope, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

Retrieved on: 
Wednesday, November 30, 2022

The Agency is currently planning to hold an advisory committee meeting to discuss this application.

Key Points: 
  • The Agency is currently planning to hold an advisory committee meeting to discuss this application.
  • SUL-DUR also exhibited a favorable safety profile with statistically significant reduction in nephrotoxicity.
  • Carbapenem-resistant and multidrug-resistant Acinetobacter infections are an urgent and emergent threat due to increasing rates of resistance and few viable treatment options.
  • Our focused and dedicated team looks forward to continuing to work with the FDA throughout the priority review process.

Here's What Happens When 25,000 Women Go Vegan Together

Retrieved on: 
Wednesday, November 30, 2022

WASHINGTON, Nov. 30, 2022 /PRNewswire/ -- Award-winning public health nutritionist, 35-year vegan activist, and best-selling author Tracye McQuirter, MPH, recently held another free 21-Day Vegan Fresh Start program from September 18 - October 9, 2022 and the results were extraordinary. 

Key Points: 
  • This marks the fourth free 21-Day Vegan Fresh Start program as part of McQuirter's 10 Million Black Vegan Women Movement , a revolutionary public health intervention that is changing the health paradigm of Black women now and for generations to come.
  • The 21-Day Vegan Fresh Start continues to attract a sizable cohort of women, with 3,705 enrolling.
  • Data shows the 21-Day Vegan Fresh Start effectively promotes, educates and prepares women to live a healthy vegan lifestyle.
  • McQuirter created 10 MIllion Black Vegan Women to change the paradigm of Black women's health.

Otsuka Medical Devices and ReCor Medical Announce Submission of Application for Pre-Market Approval of the Paradise™ Ultrasound Renal Denervation (uRDN) System to the U.S. Food and Drug Administration

Retrieved on: 
Wednesday, November 30, 2022

Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and ReCor Medical, Inc. (ReCor, subsidiary of Otsuka Medical Devices) announced the filing of the pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Paradise uRDN System in the treatment of uncontrolled hypertension.

Key Points: 
  • Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and ReCor Medical, Inc. (ReCor, subsidiary of Otsuka Medical Devices) announced the filing of the pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Paradise uRDN System in the treatment of uncontrolled hypertension.
  • Paradise uRDN uses a combination of ultrasound energy to denervate the renal nerves and a water-filled balloon to protect the renal artery.
  • Since 2009, ReCor has been focused on developing and testing the Paradise uRDN System to treat hypertension safely and effectively.
  • In September of this year, ReCor and Otsuka Medical Devices announced that the trial successfully reached its primary efficacy endpoint.